211. Hypoplastic left heart syndrome
[
16 clinical trials,
16 drugs（DrugBank:
7 drugs),
4 target genes / 13 target pathways ]
Searched query = "Hypoplastic left heart syndrome", "Single ventricular circulation syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03406884 | June 2020 | 11 November 2019 | Autologous Cardiac Stem Cell Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study. | Autologous Cardiac Stem Cell Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study. | Hypoplastic Left Heart Syndrome | Drug: c-kit+ cells;Drug: Placebo | Joshua M Hare | University of Maryland, College Park | Not recruiting | N/A | 27 Days | All | 30 | Phase 1 | United States |
| 2 | NCT04090697 | November 1, 2019 | 30 September 2019 | Use of Oxandrolone to Promote Growth in Infants With HLHS | Use of Oxandrolone to Promote Growth in Infants With Hypoplastic Left Heart Syndrome: A Phase I/II Pilot Study | Hypoplastic Left Heart;Congenital Heart Disease | Drug: Oxandrolone | New England Research Institutes | Not recruiting | N/A | 14 Days | All | 100 | Phase 1/Phase 2 | ||
| 3 | NCT03779711 | April 2019 | 25 March 2019 | Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome (AutoCell-S2) | Phase IIb Study of Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Stage II Surgical Repair of Right Ventricular Dependent Variants of Hypoplastic Left Heart Syndrome (AutoCell-S2) | Hypoplastic Left Heart Syndrome | Biological: Autologous (self) mononuclear cells derived from umbilical cord blood;Procedure: Stage II Surgical repair | Timothy J. Nelson | University of Oklahoma;Children's Hospital of Philadelphia;Children's Hospital Los Angeles;Children's Hospital Colorado;Children's Hospitals and Clinics of Minnesota | Recruiting | N/A | 8 Months | All | 100 | Phase 2 | United States |
| 4 | NCT03525418 | February 21, 2018 | 15 October 2018 | Longeveron Mesenchymal Stem Cells (LMSCs) Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS) | Allogeneic Human MEsenchymal Stem Cell (MSC) Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS) | HLHS | Biological: Longeveron Mesenchymal Stem Cells | Longeveron LLC | Recruiting | N/A | 1 Year | All | 30 | Phase 1/Phase 2 | United States | |
| 5 | NCT03431480 | February 16, 2018 | 6 May 2019 | Safety of Autologous Cord Blood Cells in HLHS Patients During Norwood Heart Surgery | Safety Study of Autologous Cord Blood Stem Cell Treatment in Hypoplastic Left Heart Syndrome Patients Undergoing the Norwood Heart Operation | Hypoplastic Left Heart Syndrome;Heart Defects, Congenital;Pediatric Disorder | Biological: Autologous Human Placental Cord Blood Mononuclear Cells | Murdoch Childrens Research Institute | Recruiting | N/A | 4 Days | All | 12 | Phase 1 | Australia | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03136835 | February 2, 2018 | 10 September 2018 | Maternal Hyperoxygenation in Congenital Heart Disease | Maternal Hyperoxygenation in Congenital Heart Disease | Hypoplastic Left Heart Syndrome | Drug: Maternal Hyperoxygenation | The Hospital for Sick Children | Recruiting | 18 Years | N/A | Female | 20 | Phase 1/Phase 2 | Canada | |
| 7 | NCT03147014 | January 1, 2016 | 18 December 2018 | Cardiovascular Response to Maternal Hyperoxygenation in Fetal Congenital Heart Disease | Cardiovascular Response to Maternal Hyperoxygenation in Fetal Congenital Heart Disease | Hypoplastic Left Heart Syndrome;Aortic Coarctation;Atrial Septal Aneurysm | Biological: Maternal hyperoxygenation | Beijing Anzhen Hospital | Recruiting | N/A | N/A | Female | 600 | N/A | China | |
| 8 | NCT02080637 | July 2015 | 11 June 2018 | Ambrisentan in Single Ventricle | Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric Patients | Hypoplastic Left Heart Syndrome;Hypoplastic Right-sided Heart Complex | Drug: Ambrisentan;Other: Placebo | Kevin Hill | Not recruiting | 24 Months | 120 Months | All | 20 | Phase 2 | United States | |
| 9 | JPRN-UMIN000017311 | 2015/05/01 | 21 May 2019 | Hypoxia inhalation therapy for infants with pulmonary congestion caused by congenital heart disease. | Hypoxia inhalation therapy for infants with pulmonary congestion caused by congenital heart disease. - Hypoxia inhalation therapy for infants | hypoplastic left heart syndrome, coarctation of aorta, interruption of aorta, truncus arteriosus, double outlet of right ventricle (Taussig-Bing anomaly), single ventricles | Hypoxia inhalation nitrogen inhalation | Institutional Review Board of Kagoshima University | Not Recruiting | 1days-old | 365days-old | Male and Female | 30 | Not selected | Japan | |
| 10 | NCT02398604 | April 2015 | 15 July 2019 | Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome | Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study. | Hypoplastic Left Heart Syndrome | Drug: Allo-hMSCs;Drug: Placebo | Joshua M Hare | University of Maryland | Not recruiting | N/A | 30 Days | All | 5 | Phase 1 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT01883076 | May 15, 2013 | 25 March 2019 | Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of Hypoplastic Left Heart Syndrome | Phase I Safety Study of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Stage II Palliation of Hypoplastic Left Heart Syndrome | Hypoplastic Left Heart Syndrome | Biological: autologous cell-based delivery | Timothy J. Nelson | University of Oklahoma;Children's Hospital of Philadelphia;Children's Hospitals and Clinics of Minnesota;Children's Hospital Los Angeles;Children's Hospital Colorado | Recruiting | N/A | 18 Months | All | 30 | Phase 1 | United States |
| 12 | NCT01445041 | September 2011 | 15 July 2019 | Safety and Feasibility Study of Umbilical Cord Blood Cells for Infants With Hypoplastic Left Heart Syndrome | Autologous Cord Blood Cells for Patients With HLHS: Phase I Study of Feasibility and Safety | Hypoplastic Left Heart Syndrome | Biological: Autologous Umbilical Cord Blood | Michael Cotten | Not recruiting | N/A | 2 Days | All | 20 | Phase 1 | United States | |
| 13 | EUCTR2010-022389-28-DK | 12/11/2010 | 12 May 2014 | Treatment with Endothelinantagonist to tcpc patients; a multicenter, randomized, Prospective study measuring maximal O2 uptake in ergometer bicycle test. [TEMPO-study]. | Treatment with Endothelinantagonist to tcpc patients; a multicenter, randomized, Prospective study measuring maximal O2 uptake in ergometer bicycle test. [TEMPO-study]. | Patients with a univentricular heart, who have recieved paliating surgery in the form of TCPC operation MedDRA version: 14.1 Level: PT Classification code 10021076 Term: Hypoplastic left heart syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders | Trade Name: Tracleer Pharmaceutical Form: Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | Lars Søndergaard | Not Recruiting | Female: yes Male: yes | Denmark | |||||
| 14 | NCT00974025 | June 2009 | 16 December 2017 | Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients | Vitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan Palliation | Fontan Procedure;Hypoplastic Left Heart Syndrome;Tricuspid Atresia | Dietary Supplement: Vitamin C;Dietary Supplement: Placebo | University of Michigan | Griese-Hutchinson Champions for Children's Hearts Investigator Award | Not recruiting | 8 Years | 25 Years | All | 53 | N/A | United States |
| 15 | NCT00507819 | December 2007 | 19 October 2017 | Sildenafil After the Fontan Operation | The Sildenafil After Fontan Operation Study | Hypoplastic Left Heart Syndrome;Tricuspid Atresia | Drug: Sildenafil;Drug: Placebo | Children's Hospital of Philadelphia | The Mark H. and Blanche M. Harrington Foundation | Not recruiting | 8 Years | 40 Years | All | 28 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT00513240 | September 2006 | 19 October 2017 | Erythropoetin Neuroprotection for Neonatal Cardiac Surgery | Erythropoetin Neuroprotection for Neonatal Cardiac Surgery | Congenital Heart Disease;Hypoplastic Left Heart Syndrome;Transposition of the Great Arteries;Aortic Arch Hypoplasia or Interruption | Drug: Erythropoetin;Drug: Normal saline | Baylor College of Medicine | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);The Dana Foundation;Texas Children's Hospital | Not recruiting | N/A | 30 Days | All | 62 | Phase 1/Phase 2 | United States |